Pulse Biosciences (NASDAQ:PLSE) Releases Earnings Results, Beats Estimates By $0.06 EPS

Pulse Biosciences (NASDAQ:PLSE) posted its quarterly earnings data on Thursday. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.06, FiscalAI reports.

Pulse Biosciences Stock Down 1.5%

Shares of NASDAQ:PLSE traded down $0.38 on Thursday, hitting $25.08. The company had a trading volume of 371,334 shares, compared to its average volume of 360,387. Pulse Biosciences has a 1 year low of $12.56 and a 1 year high of $26.30. The firm’s 50-day simple moving average is $15.98 and its two-hundred day simple moving average is $15.97. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of -22.19 and a beta of 1.77.

Analyst Upgrades and Downgrades

PLSE has been the topic of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Thursday, January 22nd. Mizuho set a $30.00 target price on shares of Pulse Biosciences in a report on Friday, February 6th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $26.00.

Insider Buying and Selling

In related news, insider Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $23.63, for a total transaction of $472,600.00. Following the sale, the insider directly owned 43,298 shares in the company, valued at $1,023,131.74. The trade was a 31.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold 80,000 shares of company stock valued at $1,876,200 in the last ninety days. Company insiders own 74.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Portolan Capital Management LLC bought a new stake in Pulse Biosciences in the 3rd quarter worth about $1,809,000. Brooklyn Investment Group boosted its holdings in shares of Pulse Biosciences by 330.7% during the 4th quarter. Brooklyn Investment Group now owns 130,340 shares of the company’s stock valued at $1,844,000 after acquiring an additional 100,081 shares during the last quarter. Tudor Investment Corp ET AL bought a new stake in shares of Pulse Biosciences in the fourth quarter worth approximately $382,000. UBS Group AG grew its stake in shares of Pulse Biosciences by 53.4% in the third quarter. UBS Group AG now owns 76,856 shares of the company’s stock worth $1,360,000 after acquiring an additional 26,739 shares during the period. Finally, State Street Corp raised its holdings in shares of Pulse Biosciences by 6.0% during the fourth quarter. State Street Corp now owns 447,067 shares of the company’s stock valued at $6,138,000 after purchasing an additional 25,187 shares during the last quarter. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.